AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Genes & Diseases Article
PDF (5 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Full Length Article | Open Access

Colony-stimulating factor-1 receptor inhibition combined with paclitaxel exerts effective antitumor effects in the treatment of ovarian cancer

Meijia Yua,b,c,,1, Yiming Wua,1, Qingfang Lia,1, Weiqi Honga, Yang Yangb, Xiaoyi Hub, Yanfei Yangb, Tianqi Lua, Xia Zhaob( ), Xiawei Weia ( )
Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China
Department of Gynecology and Obstetrics, Development and Related Disease of Women and Children Key Laboratory of Sichuan Province, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, Sichuan 610041, China
Department of Obstetrics and Gynecology, The First Affiliated Hospital, Army Medical University, Chongqing 400038, China

Peer review under responsibility of Chongqing Medical University.

1 These authors contributed equally to this work.

Show Author Information

Abstract

Ovarian cancer is the tumor with the highest mortality among gynecological malignancies. Studies have confirmed that paclitaxel chemoresistance is associated with increased infiltration of tumor-associated macrophages (TAMs) in the microenvironment. Colony-stimulating factor 1 (CSF-1) receptor (CSF-1R) plays a key role in regulating the number and differentiation of macrophages in certain solid tumors. There are few reports on the effects of targeted inhibition of CSF-1R in combination with chemotherapy on ovarian cancer and the tumor microenvironment. Here, we explored the antitumor efficacy and possible mechanisms of the CSF − 1R inhibitor pexidartinib (PLX3397) when combined with the first-line chemotherapeutic agent paclitaxel in the treatment of ovarian cancer. We found that CSF-1R is highly expressed in ovarian cancer cells and correlates with poor prognosis. Treatment by PLX3397 in combination with paclitaxel significantly inhibited the growth of ovarian cancer both in vitro and in vivo. Blockade of CSF-1R altered the macrophage phenotype and reprogrammed the immunosuppressive cell population in the tumor microenvironment.

Keywords

Tumor-associated macrophagesPaclitaxelOvarian cancerTargeted therapyCSF-1RPLX3397

References

1

Gnade C, McDonald ME. Maintenance therapy in the treatment of recurrent epithelial ovarian cancer. Clin Obstet Gynecol. 2020;63(1):86–91.
Crossref Google Scholar
2

Katsumata N, Yasuda M, Isonishi S, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 2013;14(10):1020–1026.
Crossref Google Scholar
3

Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501(7467):346–354.
Crossref Google Scholar
4

Klemm F, Joyce JA. Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol. 2015;25(4):198–213.
Crossref Google Scholar
5

Nielsen SR, Schmid MC. Macrophages as key drivers of cancer progression and metastasis. Mediat Inflamm. 2017;2017:9624760.
Crossref Google Scholar
6

Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39–51.
Crossref Google Scholar
7

DeNardo DG, Brennan DJ, Rexhepaj E, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011;1(1):54–67.
Crossref Google Scholar
8

Sherr CJ, Rettenmier CW, Sacca R, Roussel MF, Look AT, Stanley ER. The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1. Cell. 1985;41(3):665–676.
Crossref Google Scholar
9

Chitu V, Stanley ER. Colony-stimulating factor-1 in immunity and inflammation. Curr Opin Immunol. 2006;18(1):39–48.
Crossref Google Scholar
10

Stanley ER, Chitu V. CSF-1 receptor signaling in myeloid cells. Cold Spring Harbor Perspect Biol. 2014;6(6):a021857.
Crossref Google Scholar
11

Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, Rüttinger D. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer. 2017;5(1):53.
Crossref Google Scholar
12

Chang M, Hamilton JA, Scholz GM, Masendycz P, MacAulay SL, Elsegood CL. Phosphatidylinostitol-3 kinase and phospholipase C enhance CSF-1-dependent macrophage survival by controlling glucose uptake. Cell Signal. 2009;21(9):1361–1369.
Crossref Google Scholar
13

Kowalska M, Tajer J, Chechlinska M, et al. Serum macrophage colony-stimulating factor (M-CSF) in patients with Hodgkin lymphoma. Med Oncol. 2012;29(3):2143–2147.
Crossref Google Scholar
14

Chambers SK, Kacinski BM, Ivins CM, Carcangiu ML. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1. Clin Cancer Res. 1997;3(6):999–1007.
Google Scholar
15

Koh YW, Park C, Yoon DH, Suh C, Huh J. CSF-1R expression in tumor-associated macrophages is associated with worse prognosis in classical Hodgkin lymphoma. Am J Clin Pathol. 2014;141(4):573–583.
Crossref Google Scholar
16

Dougherty ST, Eaves CJ, McBride WH, Dougherty GJ. Role of macrophage-colony-stimulating factor in regulating the accumulation and phenotype of tumor-associated macrophages. Cancer Immunol Immunother. 1997;44(3):165–172.
Crossref Google Scholar
17

Alsayadi YMMA, Chawla PA. Prospects of treating tenosynovial giant cell tumor through pexidartinib: a review. Anti Cancer Agents Med Chem. 2021;21(12):1510–1519.
Crossref Google Scholar
18

Mo H, Hao Y, Lv Y, et al. Overexpression of macrophage-colony stimulating factor-1 receptor as a prognostic factor for survival in cancer. Medicine. 2021;100(12):e25218.
Crossref Google Scholar
19

Ao JY, Zhu XD, Chai ZT, et al. Colony-stimulating factor 1 receptor blockade inhibits tumor growth by altering the polarization of tumor-associated macrophages in hepatocellular carcinoma. Mol Cancer Therapeut. 2017;16(8):1544–1554.
Crossref Google Scholar
20

van der Sluis TC, Sluijter M, van Duikeren S, et al. Therapeutic peptide vaccine-induced CD8 T cells strongly modulate intratumoral macrophages required for tumor regression. Cancer Immunol Res. 2015;3(9):1042–1051.
Crossref Google Scholar
21

Erkes DA, Rosenbaum SR, Field CO, Chervoneva I, Villanueva J, Aplin AE. PLX3397 inhibits the accumulation of intra-tumoral macrophages and improves bromodomain and extra-terminal inhibitor efficacy in melanoma. Pigment Cell Melanoma Res. 2020;33(2):372–377.
Crossref Google Scholar
22

Guan W, Hu J, Yang L, et al. Inhibition of TAMs improves the response to docetaxel in castration-resistant prostate cancer. Endocr Relat Cancer. 2019;26(1):131–140.
Crossref Google Scholar
23

Yeh YM, Hsu SJ, Lin P, et al. The c.1085A>G genetic variant of CSF1R gene regulates tumor immunity by altering the proliferation, polarization, and function of macrophages. Clin Cancer Res. 2017;23:6021–6030.
Crossref Google Scholar
24

Cioce M, Canino C, Goparaju C, Yang H, Carbone M, Pass HI. Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation. Cell Death Dis. 2014;5(4):e1167.
Crossref Google Scholar
25

Banerjee S, Halder K, Bose A, et al. TLR signaling-mediated differential histone modification at IL-10 and IL-12 promoter region leads to functional impairments in tumor-associated macrophages. Carcinogenesis. 2011;32(12):1789–1797.
Crossref Google Scholar
26

Zhu D, Johnson TK, Wang Y, et al. Macrophage M2 polarization induced by exosomes from adipose-derived stem cells contributes to the exosomal proangiogenic effect on mouse ischemic hindlimb. Stem Cell Res Ther. 2020;11(1):162.
Crossref Google Scholar
27

Park JY, Sung JY, Lee J, et al. Polarized CD163+ tumor-associated macrophages are associated with increased angiogenesis and CXCL12 expression in gastric cancer. Clin Res Hepatol Gastroenterol. 2016;40(3):357–365.
Crossref Google Scholar
28

Chanmee T, Ontong P, Konno K, Itano N. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers. 2014;6(3):1670–1690.
Crossref Google Scholar
29

Sapi E. The role of CSF-1 in normal physiology of mammary gland and breast cancer: an update. Exp Biol Med. 2004;229(1):1–11.
Crossref Google Scholar
30

Kluger HM, Dolled-Filhart M, Rodov S, Kacinski BM, Camp RL, Rimm DL. Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis. Clin Cancer Res. 2004;10(1 Pt 1):173–177.
Crossref Google Scholar
31

Rohrschneider LR, Bourette RP, Lioubin MN, Algate PA, Myles GM, Carlberg K. Growth and differentiation signals regulated by the M-CSF receptor. Mol Reprod Dev. 1997;46(1):96–103.
Crossref
32

Espinosa I, Edris B, Lee CH, et al. CSF1 expression in nongynecological leiomyosarcoma is associated with increased tumor angiogenesis. Am J Pathol. 2011;179(4):2100–2107.
Crossref Google Scholar
33

Murga-Zamalloa C, Rolland DCM, Polk A, et al. Colony-stimulating factor 1 receptor (CSF1R) activates AKT/mTOR signaling and promotes T-cell lymphoma viability. Clin Cancer Res. 2020;26(3):690–703.
Crossref Google Scholar
34

Zhou Y, Yi X, Stoffer JB, et al. The multifunctional protein glyceraldehyde-3-phosphate dehydrogenase is both regulated and controls colony-stimulating factor-1 messenger RNA stability in ovarian cancer. Mol Cancer Res. 2008;6(8):1375–1384.
Crossref Google Scholar
35

Chambers SK. Role of CSF-1 in progression of epithelial ovarian cancer. Future Oncol. 2009;5(9):1429–1440.
Crossref Google Scholar
36

Gruessner C, Gruessner A, Glaser K, et al. Biomarkers and endosalpingiosis in the ovarian and tubal microenvironment of women at high-risk for pelvic serous carcinoma. Am J Cancer Res. 2014;4(1):61–72.
Google Scholar
37

Wrobel CN, Debnath J, Lin E, Beausoleil S, Roussel MF, Brugge JS. Autocrine CSF-1R activation promotes Src-dependent disruption of mammary epithelial architecture. J Cell Biol. 2004;165(2):263–273.
Crossref Google Scholar
Genes & Diseases
Volume 11 Issue 3,
May 2024
Article number: 100989
DOI: 10.1016/j.gendis.2023.04.023
Cite this article:
Yu M, Wu Y, Li Q, et al. Colony-stimulating factor-1 receptor inhibition combined with paclitaxel exerts effective antitumor effects in the treatment of ovarian cancer. Genes & Diseases, 2024, 11(3): 100989. https://doi.org/10.1016/j.gendis.2023.04.023

137

Views

4

Downloads

1

Crossref

2

Web of Science

3

Scopus

0

CSCD

Altmetrics
Received: 28 November 2022
Accepted: 08 April 2023
Published: 22 June 2023
©2024 The Authors.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Return